APC Anti-Human CD19 (HIB19)
The HIB19 antibody reacts with human CD19, a 95 kDa glycoprotein which acts as a co-receptor, along with CD21, CD81 and CD225, in support of the functional B cell receptor (BCR). This complex provides antigen-specific recognition and subsequent activation of B cells to proliferate and differentiate into antibody-secreting cells (plasma cells) or memory B cells, which are crucial for secondary antigen encounter. CD19 is a lineage-differentiation marker, as its expression is detectable at the earliest B cell stages, through development, and is finally lost upon transition to mature plasma cells.
The HIB19 antibody is widely used as a phenotypic marker for CD19 expression on B cells, as well as on dendritic cell subsets.
McMurray JL, von Borstel A, Taher TE, Syrimi E, Taylor GS, Sharif M, Rossjohn J, Remmerswaal EBM, Bemelman FJ, Vieira Braga FA, Chen X, Teichmann SA, Mohammed F, Berry AA, Lyke KE, Williamson KC, Stubbington MJT, Davey MS, Willcox CR, Willcox BE. Transcriptional profiling of human Vδ1 T cells reveals a pathogen-driven adaptive differentiation program. Cell Rep. 2022 May 24;39(8):110858. doi: 10.1016/j.celrep.2022.110858. PMID: 35613583.
|Name||APC Anti-Human CD19 (HIB19)|
|Alternative Names||Leu-12, B4|
|Isotype||Mouse IgG1, kappa|